Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

243.85 -1.32 (-0.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,196,982
Open 245.36
Bid (Size) 243.85 (3)
Ask (Size) 245.43 (21)
Prev. Close 245.17
Today's Range 243.45 - 246.52
52wk Range 214.39 - 296.67
Shares Outstanding N/A
Dividend Yield 2.89%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
Will These 3 Potential Blockbuster Drugs Lift Bristol Myers Squibb?
Bristol Myers Squibb has solid replacements for its blockbusters that are facing a patent cliff. 
Via The Motley Fool

Performance

YTD
-6.80%
-6.80%
1 Month
-9.73%
-9.73%
3 Month
-11.97%
-11.97%
6 Month
-1.39%
-1.39%
1 Year
+9.09%
+9.09%

More News

Read More
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
Via Investor's Business Daily
Top 5 Health Care Stocks That May Rally
Via Benzinga
Why Amgen Stock Wilted on Wednesday
Via The Motley Fool
Amgen Sinks On Mixed Earnings As 2023 Guidance Comes Up Short
Via Investor's Business Daily
The 7 Most Undervalued Dow Stocks to Buy in February 2023
Via InvestorPlace
Why Amgen Shares Are Falling
Via Benzinga
Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline
Via Benzinga
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
Via Investor's Business Daily
Nasdaq, S&P Futures Lower As Powell & Team Kick Off 2-Day Fed Meeting: Analyst Says Positive January Harbinger Of Good Times
Via Benzinga
Here's How Much You Would Have Made Owning Amgen Stock In The Last 15 Years
Via Benzinga
Earnings Preview: Amgen
Via Benzinga
2 Top Passive-Income Stocks to Own in 2023
Via The Motley Fool
Earnings Scheduled For January 31, 2023
Via Benzinga
Analyst Expectations for Amgen's Future
Via Benzinga
Amgen Layoffs 2023: What to Know About the Latest AMGN Job Cuts
Via InvestorPlace
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
Via Benzinga
2 Top Biotech Stocks to Buy for the Long Haul
Via The Motley Fool
Dogs of the Dow 2023: 5 Dividend Stocks for Income Investors
Via InvestorPlace
6 Dividend Growth Stocks
Via Talk Markets
3 Dividend Stocks You Can Safely Hold for Years
Via The Motley Fool
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
Via Benzinga
Building A Dividend Growth Portfolio To Meet Your Unique Needs
Via Talk Markets
Illumina Shares Tank After Annual Guidance Fall Short Of Expectations
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.